查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571808

老齡化相關性黃斑部病變市場規模、佔有率、趨勢分析報告：按產品、疾病、分銷管道、地區、細分市場預測，2024-2030

Age-related Macular Degeneration Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis), By Disease (Wet AMD, Dry AMD), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

老齡化黃斑部病變市場成長與趨勢：

根據Grand View Research, Inc.的最新報告，預計到2030年，全球老齡化黃斑部病變市場規模將達到179.9億美元，2024年至2030年複合年成長率為8.2%。

這一成長歸因於新產品開發、產品發布的高研發投資、老齡化黃斑部病變(AMD) 盛行率的上升以及老年人口的不斷成長。

尚未核准治療乾老齡化黃斑部病變的藥物。這為市場相關人員提供了解決乾性 AMD 患者未滿足的醫療需求的機會。然而，對於濕型AMD ，可以使用抗VEGF藥物來治療和防止疾病進一步惡化。

由於經常去醫院和短時間給藥，患者往往在沒有完成治療的情況下停止治療。為了滿足此類產品日益成長的需求，各大公司正在研究開發長效抗VEGF產品。 2020 年 2 月，諾華公司的 Beovu 獲得了歐盟委員會的核准，這是一種治療老齡化黃斑部病變的藥物。該藥物是一種長效藥物，第一年每 12 週給藥一次。

此外，羅氏公司的老齡化黃斑部病變治療藥物Babismo（faricimab）是一種負荷劑量製劑，注射週期為4週，於2022年1月獲得美國FDA批准用於治療核准作為老齡化相關性黃斑部病變的治療藥物。此外，2021年10月，羅氏的Susvimo獲得FDA核准，預計2022年在美國上市。這是一款專為 LUCENTIS 給藥而設計的可再填充植入，可再填充期為 6 個月。所有這些因素預計將在預測期內推動市場成長。

EYLEA 的專利到期年份在美國為 2023 年，在歐洲為 2025 年，取決於多個專利類別。 Lucentis（F. Hoffmann La Roche Ltd.）於 2020 年 6 月在美國失去專利，並於 2022 年在歐洲失去專利。因此，生物相似藥製造商正在尋找進入 AMD 市場的機會。例如，2021 年 10 月，Formycon AG 和 Bioeq AG 的Lucentis生物相似藥獲得了美國FDA 的 BLA 認可。 PDUFA 審核申請的日期定於 2022 年 8 月。所有這些因素都可能會阻礙預測期內的市場成長。

老齡化黃斑部病變市場報告亮點

  • 2023 年，Eylea 細分市場的最大市場佔有率為 47.7%。市場成長是由專利保護和高市場滲透率推動的。 Eylea 用於治療損害視網膜或黃斑部、導致視力問題的眼科疾病。
  • 醫院藥房細分市場佔據主導地位，並在 2023 年佔據最大佔有率。這種主導地位是由於老齡化黃斑部病變（AMD）盛行率和住院治療的不斷上升。
  • 濕型AMD細分市場在 2023 年佔據最大市場佔有率。老年人口的增加是影響細分市場成長的主要因素之一。據 Genentech 稱，北美每年確認約 20 萬例新濕型AMD病例。
  • 北美老齡化黃斑部病變市場在 2023 年佔據主導地位。根據美國眼科學會的數據，大約 150 萬美國患有威脅視力的晚期 AMD，1,830 萬美國患有早期 AMD。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章老齡化黃斑部病變市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 老齡化黃斑部病變市場分析工具
    • 波特的分析
    • PESTEL分析

第4章老齡化黃斑部病變市場：產品估算與趨勢分析

  • 細分儀表板
  • 老齡化黃斑部病變市場：產品變化分析，百萬美元，2023 年和 2030 年
  • Eylea
  • Lucentis
  • Beovu
  • 其他

第5章老齡化黃斑部病變市場：疾病估計與趨勢分析

  • 細分儀表板
  • 老齡化黃斑部病變市場：疾病變化分析，百萬美元，2023 年和 2030 年
  • 濕型AMD
  • 乾性AMD

第6章老齡化黃斑部病變市場：通路估算及趨勢分析

  • 細分儀表板
  • 老齡化黃斑部病變市場：分銷管道波動分析，百萬美元，2023 年和 2030 年
  • 醫院藥房
  • 專業藥房
  • 網路藥房

第7章老齡化黃斑部病變市場：區域估計及趨勢分析

  • 2023 年和 2030 年老齡化黃斑部病變市場佔有率（按地區），百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第8章 競爭格局

  • 最新趨勢與影響分析：主要市場參與企業
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Bayer AG
    • Pfizer Inc.
    • Bausch Health Companies Inc.
    • Regeneron Pharmaceuticals Inc.
    • Amgen Inc.
    • Biogen
    • Samsung Bioepis
簡介目錄
Product Code: GVR-4-68039-971-3

Age-related Macular Degeneration Market Growth & Trends:

The global age-related macular degeneration market size is expected to reach USD 17.99 billion by 2030, registering to grow at a CAGR of 8.2% from 2024 to 2030 according to a new report by Grand View Research, Inc. The growth is due to high R&D investments for new product development, product launches, rising age-related macular degeneration (AMD) prevalence, and the rising geriatric population.

There are no approved drugs available yet to treat dry age-related macular degeneration. This creates an opportunity for market players to address the unmet medical needs of dry AMD patients. However, for wet AMD, anti-VEGF drugs are used to treat and control the further deterioration of the condition.

Patients tend to discontinue their treatment without completion owing to frequent clinic visits and administration of drugs at shorter intervals. The key players are engaged in the research & development of longer acting anti-VEGF products to address the increased demand for such products. In February 2020, Novartis AG received approval for its product, Beovu, a macular degeneration drug from the European Commission for the treatment of patients with age-related macular generation. It is a long-acting drug to be administered at an interval of 12 weeks for the first year.

In addition, F. Hoffmann-La Roche Ltd.'s drug candidate, Vabysmo (faricimab), with an injection administration period of 4 weeks during loading dose; received U.S. FDA approval in January 2022 for the treatment of age-related macular degeneration. Furthermore, in October 2021, Roche's Susvimo received FDA approval and is expected to enter the U.S. in 2022. It is a refillable implant specific for LUCENTIS administration, with a refillable duration of six months. All these factors are expected to propel the market growth over the forecast period.

The patent expiry year for EYLEA is 2023 in the U.S. and 2025 in Europe, depending upon several patent categories. Lucentis (F. Hoffmann La Roche Ltd.) lost its patent in June 2020 in the U.S. and will lose patent protection in 2022 in Europe. As a result, biosimilar manufacturing companies are leveraging the opportunity to penetrate the AMD market. For instance, in October 2021, Formycon AG and Bioeq AG received the U.S. FDA acceptance of BLA for the company's biosimilar version of Lucentis. The PDUFA date for the review of the application is scheduled for August 2022. All these factors could hamper the market growth over the forecast period.

Age-related Macular Degeneration Market Report Highlights:

  • The Eylea segment accounted for the largest market share of 47.7% in 2023. The market growth is attributed to patent protection and high market penetration. Eylea is prescribed for eye conditions that harm the retina or macula leading to impaired vision.
  • The hospital pharmacy segment dominated the market and accounted for the largest share in 2023. This dominance can be attributed to the rise in the prevalence of age-related macular degeneration (AMD) and hospitalization for treatment.
  • The wet AMD segment accounted for the largest market share in 2023. The growing geriatric population is one of the major factors influencing segment growth. According to Genentech, approximately 200,000 new instances of wet AMD are identified annually in North America.
  • North America age-related macular degeneration market dominated the market in 2023. According to the American Academy of Ophthalmology, approximately 1.5 million Americans have late AMD, which is the vision-threatening type of AMD and 18.3 million Americans are affected by early AMD.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Age-Related Macular Degeneration Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Age-Related Macular Degeneration Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Age-Related Macular Degeneration Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Age-Related Macular Degeneration Market: Product Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Eylea
    • 4.3.1. Eylea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Lucentis
    • 4.4.1. Lucentis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Beovu
    • 4.5.1. Beovu Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Age-Related Macular Degeneration Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Age-Related Macular Degeneration Market: Disease Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Wet AMD
    • 5.3.1. Wet AMD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Dry AMD
    • 5.4.1. Dry AMD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Age-Related Macular Degeneration Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Age-Related Macular Degeneration Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Specialty Pharmacy
    • 6.4.1. Specialty Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacy
    • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Age-Related Macular Degeneration Market: Regional Estimates & Trend Analysis

  • 7.1. Age-Related Macular Degeneration Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. F. Hoffmann-La Roche Ltd
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Bayer AG
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Pfizer Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Bausch Health Companies Inc.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Regeneron Pharmaceuticals Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Amgen Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Biogen
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Samsung Bioepis
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives